Clinical Trial Update: Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluates the efficacy and safety of Firmonertinib versus investigator's choice of EGFR inhibitor as first-line therapy in locally adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: ArriVent BioPharma, Inc. | Conditions: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Status: RECRUITING